Cited by 973BRCA gene mutations in cancerWomen's cancer prevention and managementBreast Lesions and Carcinomas

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

Open access

Meijers-Heijboer, Hanne, van Geel, Bert, van Putten, Wim L.J., Henzen-Logmans, Sonja C., Seynaeve, Caroline, Menke-Pluymers, Marian B.E., Bartels, Carina C.M., Verhoog, Leon C., van den Ouweland, Ans M.W., Niermeijer, Martinus F., Brekelmans, Cecile T.M., Klijn, Jan G.M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200107193450301

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women. METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the women had a history of breast cancer. Seventy-six of these women eventually underwent prophylactic mastectomy, and the other 63 remained under regular surveillance. The effect of mastectomy on the incidence of breast cancer was analyzed by the Cox proportional-hazards method in which mastectomy was modeled as a time-dependent covariate. RESULTS: No cases of breast cancer were observed after prophylactic mastectomy after a mean (+/-SE) follow-up of 2.9+/-1.4 years, whereas eight breast cancers developed in women under regular surveillance after a mean follow-up of 3.0+/-1.5 years (P=0.003; hazard ratio, 0; 95 percent confidence interval, 0 to 0.36). The actuarial mean five-year incidence of breast cancer among all women in the surveillance group was 17+/-7 percent. On the basis of an exponential model, the yearly incidence of breast cancer in this group was 2.5 percent. The observed number of breast cancers in the surveillance group was consistent with the expected number (ratio of observed to expected cases, 1.2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200107193450301

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428
Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., Gold, K., Trock, B., Main, D., Lynch, J., et al. (1996) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.275.24.1885 · Cited by 840
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer
Lerman, C. E. (1996) · JAMA · doi:10.1001/jama.1996.03530480027036 · Cited by 826
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670

Show all 33 references

Research works printed but not linked: 4

Whittemore AS, 1997, Am J Hum Genet, 60, 496
Hartmann LC, 2000, Proc Am Assoc Cancer Res, 41, 222
Kriege M, 2000, Eur J Cancer, 36, S137
Zion SM, 2000, Prog Proc Am Soc Clin Oncol, 19, 441a

Sorted by citations

Items 901–970 of 970

Mastectomía de reducción de riesgo. Experiencia del Centro Mamario del Hospital Universitario Austra
Lean, I. M., Montoya, D., Varela, E. B., Morris, B. J., Barber, J., Constantino, F., D’Angelo, L., Masllorens, F., Berdinelli, D., Schejtman, D., et al. (2020) · Revista Argentina de Cirugía · doi:10.25132/raac.v112.n1.1391.es
Calidad de vida en pacientes con cáncer de mama sometidas a tratamiento reconstructivo : revisión narrativa de la literatura
Torres, L. V. A., Amaya, D. C., Duque, Z. L., & Díaz, E. O. R. (2019)
Genetic Predispositions and Prophylactic Mastectomy in Breast Cancer Patients
Soran, A., & Şenol, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-66853-2_7
Cómo crear un Departamento de Normas, Procedimientos y Organización
Ayra, L. I., Cardoso, F. L., & Oramas, J. D. L. C. M. (2002) · Partida doble
Abordagem clínica dos grupos de risco elevado para câncer de mama
Torresan, R. Z., Tiezzi, D. G., Facina, G., & dos Santos, C. C. (2019) · Femina · doi:10.61622/0100-7254473201905
“Os mais relevantes foram as publicações de Meijers-Heijboer et al.(27) e Rebbeck et al.(28) Os primeiros autores conduziram um estudo prospectivo em 139 mulheres sadias com mutações deletérias em BRCA1 e BRCA2, das quais 76 foram submetidas à MBRR e 63 permaneceram sob seguimento regular.”
Locoregional and Locally Advanced Breast Cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_30
Breast Cancer Risk-reducing Strategies in BRCA1/2 Mutation Carriers
Heemskerk‐Gerritsen, B. A. M. (2014) · EUR Research Repository (Erasmus University Rotterdam)
Genetische Beratung bei gynäkologischen Erkrankungen
Kast, K., Rhiem, K., Schmutzler, R. K., Prieshof, B., & Costa, S. D. (2012) · Springer eBooks · doi:10.1007/978-3-642-20923-9_40
Breast Cancer
Forbes, J. (2003) · Evidence-based Oncology · doi:10.1002/9780470987360.ch40
Mammakarzinom
Zielinski, C. C., Possinger, K., & Kiechle, M. (2004) · Springer eBooks · doi:10.1007/978-3-662-06670-6_43
Zusammenfassung, Schlussfolgerungen und Ausblick
(2007) · Deutscher Universitätsverlag eBooks · doi:10.1007/978-3-8350-9197-9_7
Breast Cancer
Phillips, M. B., Arun, B., & Bleyer, W. A. (2007) · Springer eBooks · doi:10.1007/978-3-540-68152-6_18
Mammakarzinom
Delorme, S., Schulz-Wendtland, R., Fuxius, S., & Sinn, H. (2006) · Springer eBooks · doi:10.1007/978-3-540-33565-8_6
Reproductive System
Hodgson, S. V., Foulkes, W. D., Eng, C., & Maher, E. R. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2375-0_6
Breast Cancer
Hayes, D. F. (2006) · TNM Online · doi:10.1002/0471463736.tnmp30.pub2
Prophylactic Mastectomy and BRCA1 or BRCA2 Gene Mutations
Fitoussi, A. D., Berry, M., Couturaud, B., & Salmon, R. J. (2009) · Springer eBooks · doi:10.1007/978-3-642-00144-4_12
Bioethics and Medicolegal Aspects in Breast Cancer Reconstruction
Urban, C. D. A., Rabinovich, Í., Hurley, J., Rietjens, M., & Anselmi, K. F. (2019) · Springer eBooks · doi:10.1007/978-3-319-62927-8_73
Genetic Disposition
Schlossbauer, T., Hellerhoff, K., Perlet, C., Raue, F., & Delorme, S. (2008) · Medical radiology · doi:10.1007/978-3-540-49831-5_15
Prophylactic mastectomy
Osborne, M. P. (2005) · Breast Cancer Online · doi:10.1017/s1470903105001100
Mastektomie
Fansa, H., & Heitmann, C. (2018) · Springer eBooks · doi:10.1007/978-3-662-57390-7_7
Strategien zur Prävention des Mammakarzinoms
Bauerschlag, D., & Ruckhäberle, E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44424-5_16
Mastectomy
Fansa, H., & Heitmann, C. (2019) · Springer eBooks · doi:10.1007/978-3-319-95468-4_7
Einführung
Christ, M. (2006) · Springer eBooks · doi:10.1007/3-540-26553-8_1
Mammectomie prophylactique et mutations des gènes BRCA1 ou BRCA2
(2008) · Springer eBooks · doi:10.1007/978-2-287-71476-4_12
In Reply:
Hoogerbrugge, N., Bult, P., & Brunner, H. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.321
Breast Surgery
Ball, E., Burger, A., & Down, S. K. (2013) · CRC Press eBooks · doi:10.1201/b16255-6
Inherited Diseases
Vnencak‐Jones, C. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00040-8
Reply
You, Y. N., Lakhani, V. T., & Wells, S. A. (2008) · World Journal of Surgery · doi:10.1007/s00268-007-9426-3
Outcome and Evaluation of Mastectomy with Axillary Dissection in Stage-II Breast Cancer: Tertiary Level Multicentered Study in Rajshahi, Bangladesh
Ahmed, D. I., Islam, P. D. M. B., Laila, R. N., & Rahman, D. M. M. (2021) · SAS Journal of Surgery · doi:10.36347/sasjs.2021.v07i06.002
Molecular Diagnostics in Cancer
Coyne, Z. L., Kalachand, R. D., Bast, R. C., Mills, G. B., & Hennessy, B. T. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm041.pub2
Principles and Practice of Surgery in Gynaecological Cancer
Das, G., Shrikhande, S. V., Chaudhari, V. A., & Kataki, A. C. (2022) · Springer eBooks · doi:10.1007/978-981-19-5860-1_6
A pivotal study on patients’ selection for BRCA1 and BRCA2 mutations by different models in Libyan breast cancer womenPreprint
Elmaihub, E. S., Alhudiri, I. M., Elzagheid, A. I., Elfagi, F., & Hassen, E. (2023) · medRxiv · doi:10.1101/2023.01.20.23284677
Women’s satisfaction and body image long-term after risk-reducing mastectomy – the partners’ perspectivePreprint
Bai, L., Arver, B. W., Johansson, H., Wickman, M., Sandelin, K., & Brandberg, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2630820/v1
Hereditary Breast Cancer Non-CDH1 Associated
Micco, R. D., Esposito, E., Accardo, G., Sibilio, A., Kouloura, A., Costa, M. J. M., & Gentilini, O. (2023) · Springer eBooks · doi:10.1007/978-3-031-21317-5_23
Mastectomy
Fansa, H. (2023) · Springer eBooks · doi:10.1007/978-3-662-65952-6_7
Mexican breast cancer consensus. Management of early breast cancer
Bargalló‐Rocha, E., Aguilar-Villanueva, S., Ahumada-Pámanes, C., Arce-Salinas, C., Álvarez‐Cano, A., Baley-Spindel, I., Bautista‐Piña, V., Cervantes-Sánchez, G., Chávez‐MacGregor, M., Esparza-Arias, N., et al. (2024) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.m24000265
Incidental finding of a BRCA2 variant following whole genome sequencing to molecularly diagnose bilateral congenital cataracts
Heppell, C., Malka, S., & Moosajee, M. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-260755
“32 34 37 The risk and management of BRCA carriers highlight the significance of a positive BRCA diagnosis.”
Breast Cancer
Moscol, G., Mitchell, M., & Hwang, R. F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009279864.014
Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?
Swan, R. E., Pitcathley, M., Dunlop, J., & Choong, W. L. (2023) · Breast Global Journal · doi:10.4103/bgj.bgj_19_23
A Case of Occult Cancer Detected after Risk-reducing Mastectomy in a BRCA2-positive Patient who Had Not Yet Developed Breast Cancer
YOSHIKAWA, T., Takehara, Y., Tsunoda, H. S., Kanomata, N., Kida, K., Takei, J., Yamauchi, H., & Yoshida, A. (2024) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.85.714
BRCA and Other Novel Mutations: Target Population and Risk Reduction Methods
Pramanik, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-7755-6_4
Breast Cancer Occurrence After Risk-reducing Mastectomies in 274 Cases: A Single Center With More Than 42 Years of Experience
Patzelt, M., Livancova, T., Thanh, X. L., Rosetzka, K., Drozd, J., & Sukop, A. (2025) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000006526
“A study with similar follow-up was conducted by Meijers-Heijboer et al, 23 who in 2001, found no incidence of breast cancer after SSMs in 139 BRCA mutation carriers.”
Prophylaxie chirurgicale mammaire chez les patientes à très haut risque de cancer du sein
Darrigues, L., Gaillard, T., Sabah, J., Saule, C., Frank, S., Pauw, A. D., Couturaud, B., Binder, J.-P., Féron, J. G., Laas, E., et al. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.01.002
The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer
Andour, L., Hagenaars, S. C., Vangangelt, K. M. H., Aalberts, J., Rebattu, V., van der Meer, D. M. A. B., Kranenbarg, E. M., Gaarenstroom, K. N., van Asperen, C. J., Tollenaar, R. A. �. �., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35444
High-Risk Screening, Genetic Testing, and Counselling
Pramanik, R., & Dhamija, E. (2025) · Springer eBooks · doi:10.1007/978-981-97-9847-6_18
Breast cancer incidence after prophylactic mastectomy: a systematic review
Sutanto, K. W., Prayogo, D. L., Wikanta, E. R., & Stephanie, I. (2025) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20251941
Polygenic risk scores to refine Breast cancer screening and prevention strategies
Roberts, E., Flaum, N., Howell, S. J., & Evans, D. G. (2025) · Personalized Medicine · doi:10.1080/17410541.2025.2581559
The role of surgery in hereditary breast cancer prevention
Díaz-Faes, J. (2003) · Revista de Oncología · doi:10.1007/bf02709985
Biomolecular Staging: Reality or Future Perspective?
Bechi, P. (2010) · Springer eBooks · doi:10.1007/978-88-470-1658-3_3
Prevention of Breast Cancer
Morrow, M., & Jordan, V. C. (2007) · Springer eBooks · doi:10.1007/978-3-540-28266-2_4
Options and Advances in Breast Reconstruction
Kim, J. Y. S., Rawlani, V., & Cheesborough, J. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5891-3_9
“The majority of high-risk patients will undergo BPM and reconstruction [ 38 ] .”
Background
Screening for Breast Cancer in Women with a Familial or Genetic Predisposition
Kriege, M., Brekelmans, C. T. M., & Klijn, J. G. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012374212-4.50051-1
Self-citation
Additional file 1 of Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
Hallsson, L. R., Sroczynski, G., Engel, J., & Siebert, U. (2023) · Figshare · doi:10.6084/m9.figshare.23583576
Additional file 2 of Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
Hallsson, L. R., Sroczynski, G., Engel, J., & Siebert, U. (2023) · Figshare · doi:10.6084/m9.figshare.23583579
Additional file 3 of Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
Hallsson, L. R., Sroczynski, G., Engel, J., & Siebert, U. (2023) · Figshare · doi:10.6084/m9.figshare.23583582
Risk-Reducing Mastectomy in BRCA1/2 and Other High-Risk Gene Carriers: Current Evidence and Practical Guidance
Lee, J. H., Ryu, J. M., Park, J. S., Kim, J. H., Cha, C., Eoh, K. J., Yang, Y., Lee, B.-Y., Han, S.-A., & Kim, S.-W. (2026) · Journal of Breast Cancer · doi:10.4048/jbc.2025.0279
Medicina basada en la evidencia y mastectomía profiláctica: nuevas perspectivas para un dilema clásico
Landín, L., Guillén, I. G., Moreda, M. L., del Caz, M. P., Simón, E., Herrero, J., Francés, M. J., & Codina, J. (2004) · Cirugía Plástica Ibero-Latinoamericana · doi:10.64869/fhkg6891
Risk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo‐Oophorectomy in BRCA1 /2 Germline Variant Carriers: A Retrospective Cohort Study From a Single German Center
Mendes, S., Yahiaoui‐Doktor, M., Fallenberg, E. M., Kiechle, M. B., & Grill, S. (2026) · Cancer Medicine · doi:10.1002/cam4.71691
“Meijers-Heijboer et colleagues stated to not have detected any breast cancer disease in the course of PBM after a mean FUP of 2.9 ± 1.4 years [16].”
Influential
Decisional regret following risk-reducing mastectomy versus surveillance among Japanese women with breast cancer carrying BRCA1/2 pathogenic variantsPreprint
Amioka, A., Teshima, M., Takaya, M., Fujimoto, M., Ikejiri, H., Sasada, S., Shigematsu, H., & MORIHITO, O. (2026) · Research Square · doi:10.21203/rs.3.rs-8900829/v1
Detection of residual fibroglandular tissue on breast MRI and associated factors in women treated with mastectomy and DIEP flap breast reconstruction
Smeins, N. N. P. M., van Rooij, J. A. F., Heuts, E. M., Houwers, J. B., Nelemans, P. J., Tuinder, S. M. H., & van Nijnatten, T. J. A. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116567
Surgical Outcomes After Risk-Reducing Mastectomy Among BRCA1 and BRCA2 Carriers
Wiberg, R., Hägglund, S., Hellquist, B. N., Rosén, A., Idahl, A., Mani, M. R., Bajalica‐Lagercrantz, S., Ehrencrona, H., Karlsson, P., Loman, N., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.2574
Breast Diseases
Camara, O., Miranda, A., & Sehouli, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-05381-7_104
Breast cancer prevention in patients with gBRCA-mutated ovarian cancer
Amann, N., Krückel, A., Brückner, L., Gocke, J., Müller, C., Heindl, F., Hack, C. C., Stumpf, K., Emons, J., Fasching, P. A., et al. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06543-4
Surveillance of mastectomies with immediate breast reconstruction: results of a survey by the French Society of Senology and Breast Pathology (SFSPM)Preprint
Houvenaeghel, G. F., Cohen, M., Rua, S., Bouteille, C., Tallet, A. R., Cowen, D. M., Souquet-Bressand, M., Chauvet, M. P., Sabiani, L., Quilichini, O., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10546450/v1
Tumor Biology, Genetic Risk, and Systemic Therapy in Familial Breast Cancer: An 8-Year Experience from a German Center for Familial Breast and Ovarian Cancer
Hatzipanagiotou, M. E., Witterauf, L., Augele, M., Fischer, A., Holzhauser, I., Schönbuchner, I., Hammer, S., Fernandez-Pacheco, M., Huber, D., Weber, B. H. F., et al. (2026) · Breast Care · doi:10.1159/brc/abrag005
“These germline mutations serve as important biomarkers for targeted therapy [5], prevention [6], and risk-reducing surgery [7].”
Chemotherapy and microsurgical-related vascular complications in DIEP flap breast reconstruction: A retrospective study
Søndberg, V. K. S., Lautrup, M. D., Saritas, S., Allen, J. E., Nielsen, H. H. R., & Bønnelykke‐Behrndtz, M. L. (2026) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2026.10.013
Mastectomy
Cordeiro, P. G., Schorr, M. C., & Allen, R. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-28175-3_3
Breast Cancer Genetics and Risk Assessment
Shannon, K. M., & Chittenden, A. B. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1267-4_1 · Cited by 1
Surgical Management of Hereditary Breast and Ovarian Cancer
Specht, M. C., Carmen, M. G. D., & Smith, B. L. (2010) · Springer eBooks · doi:10.1007/978-0-387-93846-2_4
Hereditary Breast Cancer Syndromes
Santillan, A. A., Farma, J. M., Hagmaier, R. M., Cox, C. E., & Riker, A. I. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6821-0_4

Authors: Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., Brekelmans, C. T. M., & Klijn, J. G. M.
Affiliations: Erasmus MC (NL)
ORCID: Meijers-Heijboer, Hanne
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-07-19
Volume: 345
Issue: 3
Pages: 159-164
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200107193450301
OpenAlex: W2046809735
Cited by: 973
References: 33
Citations by year: 2026: 15 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 30 · 2018: 21 · 2017: 37 · 2016: 42 · 2015: 28 · 2014: 34 · 2013: 29 · 2012: 42
FWCI: 35.85
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords: breast cancer, bilateral prophylactic mastectomy, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, breast cancer incidence, breast cancer surveillance, genetic susceptibility to cancer
MeSH terms: Adult, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoplasm Proteins, Prospective Studies, Transcription Factors, Mastectomy, Simple, Proportional Hazards Models, Genes, BRCA1, BRCA2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks